Advertisement
ISRG vs PODD
Which Stock Would AI Choose? Intuitive Surgical (ISRG) vs. Insulet (PODD) Stock Comparison
Key Takeaways
- ISRG and PODD operate in the medical devices sector, with ISRG focused on robotic-assisted surgery systems and PODD on tubeless insulin delivery for diabetes management.
- Both companies reported solid revenue growth in recent quarters, though ISRG experienced a post-earnings stock decline tied to moderating U.S. procedure growth while PODD faced sharper pressure after lowering full-year guidance due to type 2 diabetes retention challenges.
- ISRG maintains a significantly larger market capitalization and recurring revenue base from its installed system fleet compared with PODD’s more concentrated product portfolio.
- Recent market activity shows ISRG benefiting from positive clinical data on procedure outcomes, while PODD contends with execution concerns around manufacturing and patient retention.
- Sector exposure differs markedly, with ISRG tied to broader surgical adoption trends and PODD more directly linked to diabetes care reimbursement and adoption rates.
- Relative performance reflects trade-offs between ISRG’s scale and stability versus PODD’s higher-growth but more volatile profile in the current environment.
Introduction
ISRG and PODD represent two distinct plays within the healthcare equipment space, offering investors exposure to innovation in minimally invasive procedures and chronic disease management, respectively. Traders and portfolio managers often compare these names to assess relative positioning in medtech, evaluate growth sustainability amid shifting procedure volumes or patient retention, and gauge sentiment around capital deployment and competitive dynamics. This analysis examines observable factors such as recent financial results, stock price behavior, and market catalysts to highlight contrasts in scale, risk profile, and momentum for those evaluating allocation decisions across these tickers.
ISRG Overview and Recent Performance
Intuitive Surgical develops and markets the da Vinci surgical system and related instruments for robotic-assisted minimally invasive procedures across multiple specialties. The company generates revenue from system placements, instruments and accessories, and service contracts, creating a high-margin recurring stream. In recent market activity, shares experienced volatility following second-quarter results that exceeded earnings and revenue estimates, with investors reacting to slower U.S. procedure growth amid factors such as insurance changes and deferred cases. Subsequent positive developments, including publication of a large-scale study demonstrating improved patient outcomes with da Vinci versus traditional approaches, supported sentiment recovery in the latest period. International procedure expansion remained robust, contributing to overall installed-base growth and system placements.
PODD Overview and Recent Performance
Insulet Corporation manufactures and commercializes the Omnipod platform, a tubeless insulin pump system primarily serving individuals with diabetes. Revenue derives predominantly from recurring pod sales, supported by expanding adoption in both type 1 and type 2 segments domestically and internationally. Recent market activity featured strong second-quarter revenue growth that surpassed expectations, driven by customer additions and manufacturing scale efficiencies. However, management lowered full-year guidance after noting weaker retention trends in the type 2 population, prompting a significant stock adjustment. Additional context included manufacturing quality updates and leadership transitions, which contributed to ongoing price pressure amid broader sector caution.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only those demonstrating the strongest alignment with prevailing market conditions receive placement in this featured section. Available bots span a wide range of performance metrics, including varying win rates, profit factors, maximum drawdowns, and trade frequencies, with many operating across multiple timeframes and strategies. Users can review detailed statistics such as average returns, number of trades, and ticker-specific exposure to identify options suited to individual risk preferences. This resource provides transparent data on bot characteristics for market participants seeking automated approaches.
Head-to-Head Comparison
ISRG and PODD differ substantially in business model scale and revenue visibility. ISRG benefits from a large installed base of surgical systems that drive high-margin recurring instrument sales, while PODD relies on consumable pod replenishment tied to active customer counts. Growth drivers contrast as well: ISRG draws from expanding robotic surgery adoption across general and specialty procedures, whereas PODD focuses on diabetes technology uptake and reimbursement trends. Recent momentum reveals ISRG navigating post-earnings digestion with support from clinical evidence, contrasted with PODD’s sharper reaction to guidance revisions around retention metrics. Risk factors include ISRG’s sensitivity to hospital capital budgets and procedure volumes, versus PODD’s exposure to manufacturing execution, regulatory scrutiny, and segment-specific utilization rates. Sector sentiment currently favors stability in established platforms like ISRG’s, while PODD contends with nearer-term execution questions despite international expansion potential.
Tickeron AI Verdict
Based on observable factors including trend consistency in procedure volumes, stability of recurring revenue streams, and relative positioning after recent catalysts, Tickeron’s AI models currently assign a probabilistic preference toward ISRG. The company’s broader installed base and clinical data momentum provide a more consistent backdrop compared with PODD’s recent guidance adjustments and retention variability. This assessment reflects measurable differences in volatility patterns and sector exposure rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISRG is a Buy and PODD is a Hold.
ISRG | PODD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | 100 | |
SMR RATING 1..100 | 51 | 37 | |
PRICE GROWTH RATING 1..100 | 53 | 65 | |
P/E GROWTH RATING 1..100 | 66 | 98 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PODD's Valuation (75) in the Medical Specialties industry is in the same range as ISRG (76). This means that PODD’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (87) in the Medical Specialties industry is in the same range as PODD (100). This means that ISRG’s stock grew similarly to PODD’s over the last 12 months.
PODD's SMR Rating (37) in the Medical Specialties industry is in the same range as ISRG (51). This means that PODD’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Price Growth Rating (53) in the Medical Specialties industry is in the same range as PODD (65). This means that ISRG’s stock grew similarly to PODD’s over the last 12 months.
ISRG's P/E Growth Rating (66) in the Medical Specialties industry is in the same range as PODD (98). This means that ISRG’s stock grew similarly to PODD’s over the last 12 months.
| ISRG | PODD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 29% | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 80% |
| Advances ODDS (%) | 5 days ago 67% | 16 days ago 68% |
| Declines ODDS (%) | 2 days ago 61% | 3 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 44% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green while PODD’s FA Score has 0 green FA rating(s).
- ISRG’s FA Score: 0 green, 5 red.
- PODD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 5 TA indicator(s) are bullish while PODD’s TA Score has 4 bullish TA indicator(s).
- ISRG’s TA Score: 5 bullish, 5 bearish.
- PODD’s TA Score: 4 bullish, 4 bearish.
Price Growth
ISRG (@Pharmaceuticals: Other) experienced а +0.43% price change this week, while PODD (@Medical/Nursing Services) price change was -3.68% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.16%. For the same industry, the average monthly price growth was -5.15%, and the average quarterly price growth was +14.09%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
Reported Earning Dates
ISRG is expected to report earnings on Oct 20, 2026.
PODD is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.16% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -1.33% | ||
| BSX - ISRG | 73% Closely correlated | -0.96% | ||
| SYK - ISRG | 64% Loosely correlated | -0.88% | ||
| NTRA - ISRG | 54% Loosely correlated | -1.17% | ||
| GKOS - ISRG | 51% Loosely correlated | -0.62% | ||
| PODD - ISRG | 49% Loosely correlated | +0.25% | ||
More | ||||
PODD and
Correlation & Price change
A.I.dvisor indicates that over the last year, PODD has been loosely correlated with ISRG. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PODD jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To PODD | 1D Price Change % | ||
|---|---|---|---|---|
| PODD | 100% | +0.25% | ||
| ISRG - PODD | 49% Loosely correlated | -1.33% | ||
| ATEC - PODD | 42% Loosely correlated | -4.07% | ||
| DXCM - PODD | 42% Loosely correlated | -0.07% | ||
| MDT - PODD | 41% Loosely correlated | +0.17% | ||
| SIBN - PODD | 41% Loosely correlated | -2.07% | ||
More | ||||